Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

Tolebrutinib is one of several oral BTK drugs that have been in clinical development for MS, alongside Merck KGaA's evobrutinib, Roche's fenebrutinib, Novartis' remibrutinib, and InnoCare Pharma's ...

Tolebrutinib was one of three oral BTK inhibitors that Sanofi acquired as part of its $3.7 billion buyout of Principia Biopharma in 2020, and was abandoned as a treatment for myasthenia gravis ...

According to Reed, Sanofi has prioritized multiple potentially transformative therapies in areas of high unmet patient need, including Dupixent, the world's first targeted biological agent that has ...

Sanofi‘s oral BTK inhibitor tolebrutinib significantly delayed the onset of six-month confirmed disability progression compared with a placebo, by 31%, in people with nonrelapsing secondary ...

Barclays analyst Emily Field lowered the firm’s price target on Sanofi (SNY) to EUR 115 from EUR 125 and keeps an Overweight rating on the shares.

Get the latest CytomX Therapeutics, Inc. (CTMX) stock news and headlines to help you in your trading and investing decisions.